Article info

Original research
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Authors

  1. Correspondence to Dr Thomas Yau; tyaucc{at}hku.hk
View Full Text

Citation

Wong JSL, Kwok GGW, Tang V, et al
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Publication history

  • Accepted December 26, 2020
  • First published February 9, 2021.
Online issue publication 
January 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.